Fox Run Management L.L.C. Purchases Shares of 16,667 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Fox Run Management L.L.C. purchased a new position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 16,667 shares of the biopharmaceutical company’s stock, valued at approximately $1,392,000.

Other large investors also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. increased its holdings in shares of Intra-Cellular Therapies by 10.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 22,480 shares of the biopharmaceutical company’s stock worth $1,878,000 after acquiring an additional 2,157 shares during the last quarter. Barclays PLC boosted its position in Intra-Cellular Therapies by 282.0% during the third quarter. Barclays PLC now owns 34,453 shares of the biopharmaceutical company’s stock worth $2,521,000 after purchasing an additional 25,435 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in shares of Intra-Cellular Therapies by 31.9% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 454,538 shares of the biopharmaceutical company’s stock valued at $33,258,000 after purchasing an additional 109,892 shares during the last quarter. Oak Ridge Investments LLC raised its position in shares of Intra-Cellular Therapies by 74.1% in the fourth quarter. Oak Ridge Investments LLC now owns 19,831 shares of the biopharmaceutical company’s stock valued at $1,656,000 after purchasing an additional 8,440 shares during the period. Finally, Cynosure Group LLC lifted its stake in shares of Intra-Cellular Therapies by 161.0% during the 3rd quarter. Cynosure Group LLC now owns 14,442 shares of the biopharmaceutical company’s stock worth $1,057,000 after buying an additional 8,909 shares during the last quarter. Institutional investors and hedge funds own 92.33% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Mizuho cut shares of Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and reduced their target price for the company from $140.00 to $132.00 in a research report on Monday, February 24th. StockNews.com assumed coverage on shares of Intra-Cellular Therapies in a research report on Thursday. They set a “hold” rating on the stock. Piper Sandler reiterated a “neutral” rating and issued a $132.00 price target (up from $107.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, January 14th. Leerink Partnrs downgraded Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and set a $132.00 target price (up from $108.00) on shares of Intra-Cellular Therapies in a research report on Wednesday, January 22nd. Ten analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Intra-Cellular Therapies has an average rating of “Hold” and an average price target of $106.08.

Intra-Cellular Therapies Price Performance

Shares of NASDAQ:ITCI opened at $131.65 on Friday. The firm has a 50 day simple moving average of $128.61 and a 200 day simple moving average of $97.41. The company has a market cap of $14.00 billion, a price-to-earnings ratio of -151.32 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a one year low of $64.09 and a one year high of $131.67.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The firm had revenue of $199.22 million for the quarter, compared to analyst estimates of $205.08 million. As a group, analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.